Zobrazeno 1 - 10
of 14
pro vyhledávání: '"John Scholler"'
Autor:
Khatuna Gabunia, Stephen J. Schuster, Noelle V. Frey, David L. Porter, Nektarios Kostopoulos, Simon F. Lacey, Carl H. June, Andrea Facciabene, Raymone Pajarillo, Mireia Uribe-Herranz, Vijay Bhoj, Guido Ghilardi, Kalpana Parvathaneni, Elise A. Chong, John Scholler, Marco Ruella, Silvia Beghi, Yong Gu Gu Lee, Kimberly Amelsberg
Publikováno v:
Blood. 138:163-163
Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy has revolutionized the treatment of B-cell malignancies. However, a significant subset of these patients either fails to respond or eventually relapses. Moreover, in solid cancers, CAR
Autor:
Richard Bonneau, Shannon E. McGettigan, Sonia Guedan, Xi Chen, Carmine Carpenito, John Scholler, Avery D. Posey, Aviv Madar, Carl H. June, Nathalie Scholler, Jihyun Lee, Matthew J. Frigault
Publikováno v:
Blood. 124:1070-1080
With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR) T cells has been limited, and CAR T cells have not been shown to expand and persist in patients with nonlymphoid tumors. Here we demonstrate that redir
Autor:
Yong Li, David L. Porter, Stephan A. Grupp, Gwenn Danet-Desnoyers, Michael Kalos, John Scholler, Saar Gill, Carl H. June, Olga Shestova, Marco Ruella, Martin Carroll, Sarah K. Tasian
Publikováno v:
Blood. 123(15)
Many patients with acute myeloid leukemia (AML) are incurable with chemotherapy and may benefit from novel approaches. One such approach involves the transfer of T cells engineered to express chimeric antigen receptors (CARs) for a specific cell-surf
Autor:
Prachi R. Patel, Jun Xu, Christopher L. Nobles, Stephan A. Grupp, Carl H. June, David M. Barrett, Irina Kulikovskaya, Shannon L. Maude, Simon F. Lacey, David E Ambrose, Tyler J. Reich, Farzana Nazimuddin, Bruce L. Levine, Joseph A. Fraietta, Frederic D. Bushman, Elena Orlando, John Scholler, Saar Gill, Marco Ruella, J. Joseph Melenhorst
Publikováno v:
Blood. 128:281-281
T cells bearing a second-generation anti-CD19 chimeric antigen receptor (CAR) induce complete remission in >90% of patients with acute lymphoblastic leukemia (ALL) at our institution. However, disease may recur and we recently identified two molecula
Autor:
Riikka Havunen, Shannon E. McGettigan, Keisuke Watanabe, Yangpin Luo, John Scholler, Mikko Siurala, Akseli Hemminki, Carl H. June, Sonia Guedan, Siri Tähtinen, Suvi Parviainen
Publikováno v:
Blood. 128:3360-3360
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has shown significant efficacy in hematological malignancies, however, the efficacy against solid tumors remains limited. Immunosuppression caused by the tumor microenvironment or poor infi
Autor:
Katherine T. Marcucci, Mala K. Talekar, Claire White, Jennifer Brogdon, Carl H. June, Noelle V. Frey, J. Joseph Melenhorst, Regina M. Young, Susan R. Rheingold, David L. Porter, Pamela A. Shaw, Diane Baniewicz, Colleen Callahan, Simon F. Lacey, David M. Barrett, Shannon L. Maude, Bruce L. Levine, David T. Teachey, Stephan A. Grupp, John Scholler, Richard Aplenc
Publikováno v:
Blood. 128:217-217
Background Targeted immunotherapy with CTL019, CD19-specific chimeric antigen receptor (CAR)-modified T cells, can produce potent and sustained responses in children with relapsed/refractory acute lymphoblastic leukemia (ALL). However, a subset of pa
Autor:
Felipe Bedoya, David M. Barrett, Joseph A. Fraietta, J. Joseph Melenhorst, Michael C. Milone, Simon F. Lacey, Patel Prachi, S. Grupp, Bruce L. Levine, Selene Nunez-Cruz, John Scholler, Saba Ghassemi, Carl H. June
Publikováno v:
Blood. 128:4549-4549
Adoptive cell therapy employing T cells equipped with a chimeric antigen receptor (CAR) containing a single chain antibody fragment fused to T cell signaling domains 4-1BB and CD3zeta (CTL019) has shown great potency against various hematopoietic mal
Autor:
John Scholler, Mauro Castellarin, Yangbing Zhao, Joseph A. Fraietta, Carl H. June, Jihyun Lee
Publikováno v:
Blood. 126:5432-5432
Chimeric antigen receptor (CAR) engineered T cells have been used clinically to improve outcomes in patients with hematopoietic malignancies owing to the ability of CAR T cells to recognize tumor antigens and kill malignant cells. CAR T cells possess
Autor:
David M. Barrett, Bruce L. Levine, Katherine T. Marcucci, Jennifer Brogdon, Regina M. Young, Irina Kulikovskaya, Susan R. Rheingold, Farzana Nazimuddin, Carl H. June, Maya Mudambi, David L. Porter, Pamela A. Shaw, Colleen Callahan, Richard Aplenc, Christine Barker, Andreas Loew, Zhaohui Zheng, David E Ambrose, Simon F. Lacey, J. Joseph Melenhorst, John Scholler, Jeffrey Finklestein, Shannon L. Maude, David T. Teachey, Stephan A. Grupp
Publikováno v:
Blood. 126:683-683
Background Targeted immunotherapy with T cells expressing a chimeric antigen receptor (CAR) can produce dramatic anti-tumor responses. We previously demonstrated complete remissions (CRs), prolonged persistence, and sustained responses in children an
Autor:
Jessica Perazzelli, Christopher A. Hunter, Ted J. Hofmann, Carl H. June, David A. Christian, David L. Porter, Farzana Nazimuddin, Stephan A. Grupp, J. Joseph Melenhorst, Saad S. Kenderian, Olga Shestova, Marco Ruella, Simon F. Lacey, John Scholler, Saar Gill, David M. Barrett
Publikováno v:
Blood. 126:2523-2523
Introduction: Anti-CD19 chimeric antigen receptor T cells (CART19) and bi-specific anti-CD19/CD3 antibodies (blinatumomab) generate unprecedented complete response rates of 45-90% in relapsing/refractory acute lymphoblastic leukemia (r/r B-ALL). Howe